Melanoma Antigen Family D, 1 (MAGED1) (Middle Region) Peptide
MAGED1
Reactivité: Humain
Hôte: Synthetic
BP, WB
N° du produit ABIN5513402
150,78 €
Plus frais de livraison 40,00 € et TVA
100 μg
Destination:
France
Envoi sous 15 à 22 jours ouvrables
Aperçu rapide pour Melanoma Antigen Family D, 1 (MAGED1) (Middle Region) Peptide (ABIN5513402)
Antigène
MAGED1
(Melanoma Antigen Family D, 1 (MAGED1))
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- Middle Region
-
Séquence
- WQNPPGWQTP PGWQTPPGWQ GPPDWQGPPD WPLPPDWPLP PDWPLPTDWP
-
Attributs du produit
- This is a synthetic peptide designed for use in combination with anti- MAGED1 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
-
-
-
Indications d'application
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Stock
- -20 °C
-
Stockage commentaire
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- MAGED1 (Melanoma Antigen Family D, 1 (MAGED1))
-
Sujet
-
This gene is a member of the melanoma antigen gene (MAGE) family. Most of the genes of this family encode tumor specific antigens that are not expressed in normal adult tissues except testis. Although the protein encoded by this gene shares strong homology with members of the MAGE family, it is expressed in almost all normal adult tissues. This gene has been demonstrated to be involved in the p75 neurotrophin receptor mediated programmed cell death pathway. Three transcript variants encoding two different isoforms have been found for this gene.
Alias Symbols: NRAGE, DLXIN-1
Protein Size: 778 -
ID gène
- 9500
-
NCBI Accession
- NM_001005332, NP_001005332
-
UniProt
- Q9Y5V3
Antigène
-
Vous êtes ici:
